enzalutamide Side Effects

What the FAERS Data Reveals About enzalutamide Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 57,614 voluntary reports linked to enzalutamide and its brand equivalents (Xtandi), spanning 2012 through 2025. Of those, 11,299 (19.6%) listed death as an outcome and 10,853 (18.8%) involved hospitalization. The most common indication reported alongside adverse events was Prostate Cancer.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 1% were female and 99% male; age distribution skews toward 75+, with 18,413 reports in that bracket. The single most reported reaction is fatigue with 10,159 submissions, followed by death and malignant neoplasm progression.

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.